Literature DB >> 30456623

Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO.

L Vignozzi1, N Malavolta2, P Villa3, G Mangili4, S Migliaccio5, S Lello6.   

Abstract

Entities:  

Keywords:  Fragility fractures; HRT; Osteoporosis; Quality of life; SERMs; T-SEC; Tibolone

Mesh：

Year:  2018        PMID： 30456623     DOI： 10.1007/s40618-018-0978-x

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  88 in total

1.  The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study.

Authors:  K M Prestwood; A M Kenny; C Unson; M Kulldorff
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

2.  Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Authors:  P Ravn; M Bidstrup; R D Wasnich; J W Davis; M R McClung; A Balske; C Coupland; O Sahota; A Kaur; M Daley; G Cizza
Journal:  Ann Intern Med       Date:  1999-12-21       Impact factor: 25.391

Review 3.  Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.

Authors:  D J Torgerson; S E Bell-Syer
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

4.  HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial.

Authors:  M H Komulainen; H Kröger; M T Tuppurainen; A M Heikkinen; E Alhava; R Honkanen; S Saarikoski
Journal:  Maturitas       Date:  1998-11-30       Impact factor: 4.342

5.  Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD.

Authors:  S Srivastava; M N Weitzmann; S Cenci; F P Ross; S Adler; R Pacifici
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 6.  The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.

Authors:  P D Delmas; R Eastell; P Garnero; M J Seibel; J Stepan
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

7.  The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone.

Authors:  B Lees; J C Stevenson
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

8.  A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group.

Authors:  S R Weiss; H Ellman; M Dolker
Journal:  Obstet Gynecol       Date:  1999-09       Impact factor: 7.661

9.  Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression.

Authors:  N K Shevde; A C Bendixen; K M Dienger; J W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

10.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272
View more
  1 in total

Review 1.  "Bridging the Gap" Everything that Could Have Been Avoided If We Had Applied Gender Medicine, Pharmacogenetics and Personalized Medicine in the Gender-Omics and Sex-Omics Era.

Authors:  Donato Gemmati; Katia Varani; Barbara Bramanti; Roberta Piva; Gloria Bonaccorsi; Alessandro Trentini; Maria Cristina Manfrinato; Veronica Tisato; Alessandra Carè; Tiziana Bellini
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.